David Johnson Biography and Net Worth

Director of Exelixis


David E. Johnson has been a director since May 2023. Mr. Johnson has served as the Managing Partner of Caligan Partners LP, an SEC-registered investment adviser, since 2017. Mr. Johnson has also served as a member of the board of directors of Liquidia Corporation, a biopharmaceutical company, since 2021, and served as a member of the board of directors of AMAG Pharmaceuticals, Inc., a pharmaceutical company specializing in products treating iron deficiency anemia, from 2019 to 2020. Previously, Mr. Johnson served as Managing Director at the Carlyle Group, a global private equity, alternative asset management and financial services firm, from 2010 to 2017. Before joining Carlyle Group, he served as Vice President in the Principal Investments area at Morgan Stanley, a global financial services and investment management firm, from 2004 to 2010. Prior to joining Morgan Stanley, Mr. Johnson worked at Weiss Asset Management, an investment management firm, from September 2003 to June 2004. In the not-for-profit sector, Mr. Johnson serves as a member of the board of directors of The Children’s Scholarship Fund, Inc., a privately funded tuition assistance program, and previously served on the Executive Committee for the Harvard College Fund. Mr. Johnson holds an A.B. and S.M. in Applied Mathematics from Harvard University.

What is David Edward Johnson's net worth?

The estimated net worth of David Edward Johnson is at least $24.79 million as of February 21st, 2024. Mr. Johnson owns 1,100,730 shares of Exelixis stock worth more than $24,788,440 as of April 21st. This net worth evaluation does not reflect any other investments that Mr. Johnson may own. Learn More about David Edward Johnson's net worth.

How do I contact David Edward Johnson?

The corporate mailing address for Mr. Johnson and other Exelixis executives is 1851 Harbor Bay Parkway, Alameda CA, 94502. Exelixis can also be reached via phone at (650) 837-7000 and via email at [email protected]. Learn More on David Edward Johnson's contact information.

Has David Edward Johnson been buying or selling shares of Exelixis?

David Edward Johnson has not been actively trading shares of Exelixis during the past quarter. Most recently, on Wednesday, February 21st, David Edward Johnson bought 190,000 shares of Exelixis stock. The stock was acquired at an average cost of $20.70 per share, with a total value of $3,933,000.00. Following the completion of the transaction, the director now directly owns 1,100,730 shares of the company's stock, valued at $22,785,111. Learn More on David Edward Johnson's trading history.

Who are Exelixis' active insiders?

Exelixis' insider roster includes Dana Aftab (EVP), Charles Cohen (Director), Carl Feldbaum (Director), Alan Garber (Director), Patrick Haley (EVP), Jeffrey Hessekiel (EVP), David Johnson (Director), Peter Lamb (EVP), Vincent Marchesi (Director), Michael Morrissey (CEO), Stelios Papadopoulos (Director), George Poste (Director), Gisela Schwab (CMO), Christopher Senner (CFO), Lance Willsey (Director), and Jack Wyszomierski (Director). Learn More on Exelixis' active insiders.

Are insiders buying or selling shares of Exelixis?

In the last year, Exelixis insiders bought shares 2 times. They purchased a total of 310,409 shares worth more than $6,535,038.49. In the last year, insiders at the biotechnology company sold shares 10 times. They sold a total of 331,237 shares worth more than $7,116,373.36. The most recent insider tranaction occured on March, 21st when Director Alan M Garber sold 19,205 shares worth more than $461,112.05. Insiders at Exelixis own 2.9% of the company. Learn More about insider trades at Exelixis.

Information on this page was last updated on 3/21/2024.

David Edward Johnson Insider Trading History at Exelixis

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/21/2024Buy190,000$20.70$3,933,000.001,100,730View SEC Filing Icon  
11/27/2023Buy120,409$21.61$2,602,038.49910,730View SEC Filing Icon  
See Full Table

David Edward Johnson Buying and Selling Activity at Exelixis

This chart shows David Edward Johnson's buying and selling at Exelixis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Exelixis Company Overview

Exelixis logo
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Read More

Today's Range

Now: $22.52
Low: $22.23
High: $22.71

50 Day Range

MA: $22.50
Low: $20.23
High: $23.92

2 Week Range

Now: $22.52
Low: $18.08
High: $24.34

Volume

2,329,664 shs

Average Volume

1,932,881 shs

Market Capitalization

$6.83 billion

P/E Ratio

35.19

Dividend Yield

N/A

Beta

0.54